← All trials
NCT04809766
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2021
- Primary completion
- Nov 10, 2022
- Completion date
- Nov 10, 2037
- First posted
- Mar 22, 2021
- Last posted
- Nov 17, 2021
- Enrollment
- 15
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonOverall official - principal investigator
- LonzaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.